Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Account Payables: 2021-2025

Historic Change in Account Payables for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to -$33,000.

  • Amylyx Pharmaceuticals' Change in Account Payables rose 99.05% to -$33,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 137.38%. This contributed to the annual value of -$19.1 million for FY2024, which is 220.27% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Change in Account Payables stood at -$33,000 for Q3 2025, which was up 97.85% from -$1.5 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Change in Account Payables' 5-year high stood at $15.8 million during Q4 2023, with a 5-year trough of -$18.4 million in Q3 2023.
  • Over the past 3 years, Amylyx Pharmaceuticals' median Change in Account Payables value was -$33,000 (recorded in 2025), while the average stood at -$265,000.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Change in Account Payables skyrocketed by 2,736.16% in 2022 and then crashed by 1,570.57% in 2023.
  • Over the past 5 years, Amylyx Pharmaceuticals' Change in Account Payables (Quarterly) stood at $1.4 million in 2021, then slumped by 157.72% to -$800,000 in 2022, then soared by 2,077.50% to $15.8 million in 2023, then plummeted by 90.70% to $1.5 million in 2024, then soared by 99.05% to -$33,000 in 2025.
  • Its Change in Account Payables stands at -$33,000 for Q3 2025, versus -$1.5 million for Q2 2025 and $1.9 million for Q1 2025.